CN103123319B - 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 - Google Patents
心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 Download PDFInfo
- Publication number
- CN103123319B CN103123319B CN201210557386.7A CN201210557386A CN103123319B CN 103123319 B CN103123319 B CN 103123319B CN 201210557386 A CN201210557386 A CN 201210557386A CN 103123319 B CN103123319 B CN 103123319B
- Authority
- CN
- China
- Prior art keywords
- reagent
- fatty acid
- binding protein
- acid binding
- latex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 title abstract 4
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 title abstract 4
- 239000004816 latex Substances 0.000 claims abstract description 116
- 229920000126 latex Polymers 0.000 claims abstract description 116
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 17
- 238000007789 sealing Methods 0.000 claims abstract description 15
- 230000035945 sensitivity Effects 0.000 claims abstract description 10
- 239000002981 blocking agent Substances 0.000 claims abstract description 9
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims description 74
- 108091022862 fatty acid binding Proteins 0.000 claims description 74
- 239000000243 solution Substances 0.000 claims description 68
- 239000002245 particle Substances 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 239000012153 distilled water Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 21
- -1 antiseptic Substances 0.000 claims description 16
- 230000002421 anti-septic effect Effects 0.000 claims description 15
- 239000006177 biological buffer Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000003352 sequestering agent Substances 0.000 claims description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 14
- 239000004793 Polystyrene Substances 0.000 claims description 12
- 150000001718 carbodiimides Chemical group 0.000 claims description 12
- 229920002223 polystyrene Polymers 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 239000000375 suspending agent Substances 0.000 claims description 10
- 239000012467 final product Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 206010070834 Sensitisation Diseases 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 230000008313 sensitization Effects 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000006172 buffering agent Substances 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 24
- 230000009514 concussion Effects 0.000 description 22
- 239000000523 sample Substances 0.000 description 16
- 229910019142 PO4 Inorganic materials 0.000 description 15
- 239000008366 buffered solution Substances 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 15
- 239000010452 phosphate Substances 0.000 description 15
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001235 sensitizing effect Effects 0.000 description 6
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical class CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 5
- 239000012901 Milli-Q water Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002331 protein detection Methods 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000004879 turbidimetry Methods 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 2
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 101710086566 T-box transcription factor T Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
类风湿因子浓度(U/mL) | 0 | 100 | 200 | 300 | 500 |
本发明试剂盒测量均值 | 80 | 82.5 | 83.1 | 84.3 | 85.7 |
本发明试剂盒测量偏差(%) | 0.0 | 3.13 | 3.88 | 5.38 | 7.13 |
对比实施例测量均值 | 78.9 | 84.5 | 87.2 | 89.4 | 91.8 |
对比实施例测量偏差(%) | -1.38 | 5.63 | 9.00 | 11.75 | 14.75 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210557386.7A CN103123319B (zh) | 2012-12-20 | 2012-12-20 | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210557386.7A CN103123319B (zh) | 2012-12-20 | 2012-12-20 | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103123319A CN103123319A (zh) | 2013-05-29 |
CN103123319B true CN103123319B (zh) | 2015-04-15 |
Family
ID=48454379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210557386.7A Active CN103123319B (zh) | 2012-12-20 | 2012-12-20 | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103123319B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103308681B (zh) * | 2013-06-25 | 2015-07-29 | 武汉生之源生物科技有限公司 | 胰蛋白酶原-2检测试剂盒及制备方法 |
CN103529225B (zh) * | 2013-11-04 | 2016-01-13 | 武汉华美生物工程有限公司 | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
CN104483475A (zh) * | 2014-12-22 | 2015-04-01 | 宁波美康生物科技股份有限公司 | 纤维结合蛋白检测试剂盒 |
CN104807990A (zh) * | 2015-05-12 | 2015-07-29 | 骏实生物科技(上海)有限公司 | 一种用于抗原抗体反应体外诊断试剂的热稳定剂 |
CN106093417A (zh) * | 2016-05-26 | 2016-11-09 | 安徽伊普诺康生物技术股份有限公司 | 一种测定纤维结合蛋白的试剂盒及其制备方法 |
CN105929176A (zh) * | 2016-05-26 | 2016-09-07 | 安徽伊普诺康生物技术股份有限公司 | 一种测定心型脂肪酸结合蛋白的试剂盒及其制备方法 |
CN106442355A (zh) * | 2016-09-29 | 2017-02-22 | 浙江达美生物技术有限公司 | 心型脂肪酸结合蛋白的测定试剂及其制备方法 |
CN106950363A (zh) * | 2017-03-31 | 2017-07-14 | 四川迈克生物科技股份有限公司 | 抑制类风湿因子干扰的胶乳增强免疫比浊试剂 |
CN108627652B (zh) * | 2018-05-31 | 2019-05-03 | 宁波海壹生物科技有限公司 | 一种基于单粒径并可同时检测血清和尿液样本中视黄醇结合蛋白的试剂盒 |
CN108982827A (zh) * | 2018-06-26 | 2018-12-11 | 浙江卓运生物科技有限公司 | 一种胶乳免疫比浊试剂 |
CN109142749A (zh) * | 2018-08-11 | 2019-01-04 | 金华市强盛生物科技有限公司 | 一种心型脂肪酸结合蛋白检测试剂盒 |
CN111239403B (zh) * | 2019-02-13 | 2020-12-08 | 武汉生之源生物科技股份有限公司 | 一种β2微球蛋白胶乳增强免疫比浊试剂盒及应用 |
CN113125749B (zh) * | 2021-03-30 | 2024-07-16 | 潍坊三维生物工程集团有限公司 | 一种用于检测血清糖化白蛋白的试剂盒 |
CN113125748B (zh) * | 2021-03-30 | 2024-07-16 | 潍坊三维生物工程集团有限公司 | 一种用于检测心脏型脂肪酸结合蛋白的试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102422159A (zh) * | 2009-06-30 | 2012-04-18 | 积水医疗株式会社 | 用于kl-6测定的免疫测定试剂 |
CN102608325A (zh) * | 2012-02-24 | 2012-07-25 | 南京诺尔曼生物技术有限公司 | 脂肪酸结合蛋白(fatty acid-binding proteins,H-FABP)测定试剂盒(胶乳增强免疫比浊法) |
CN102628864A (zh) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | 胶乳增强免疫比浊法测定血清或尿液中心脏型脂肪酸结合蛋白的试剂盒 |
CN102788880A (zh) * | 2012-08-16 | 2012-11-21 | 北京恩济和生物科技有限公司 | 一种心型脂肪酸结合蛋白检测试剂盒及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050250156A1 (en) * | 2003-10-31 | 2005-11-10 | Shebuski Ronald J | Detection of acute myocardial infarction biomarkers |
-
2012
- 2012-12-20 CN CN201210557386.7A patent/CN103123319B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102422159A (zh) * | 2009-06-30 | 2012-04-18 | 积水医疗株式会社 | 用于kl-6测定的免疫测定试剂 |
CN102628864A (zh) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | 胶乳增强免疫比浊法测定血清或尿液中心脏型脂肪酸结合蛋白的试剂盒 |
CN102608325A (zh) * | 2012-02-24 | 2012-07-25 | 南京诺尔曼生物技术有限公司 | 脂肪酸结合蛋白(fatty acid-binding proteins,H-FABP)测定试剂盒(胶乳增强免疫比浊法) |
CN102788880A (zh) * | 2012-08-16 | 2012-11-21 | 北京恩济和生物科技有限公司 | 一种心型脂肪酸结合蛋白检测试剂盒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103123319A (zh) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103123319B (zh) | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 | |
CN103048464B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其制备方法 | |
CN103604930B (zh) | 一种脂蛋白(a)检测试剂盒 | |
CN104198723A (zh) | 一种基于氨基酸间臂的ngal快速检测试剂盒 | |
CN103323596B (zh) | 髓过氧化物酶含量检测试剂盒及其制备方法 | |
EP2295969B1 (en) | Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement | |
CN110736837B (zh) | 神经元特异性烯醇化酶的胶乳免疫比浊检测试剂盒 | |
CN111057150B (zh) | 一种乳胶微球及其应用以及糖化血红蛋白检测试剂盒 | |
CN111337691A (zh) | 一种灵敏、稳定的血清降钙素原测定试剂盒及其制备方法和应用 | |
CN112014577B (zh) | 一种提高gpc3检测灵敏度的试剂盒及其制备方法 | |
CN104535770A (zh) | 一种复合抗体的肌红蛋白测定试剂盒 | |
CN110806487A (zh) | 一种用于人肝素结合蛋白检测的试剂盒及其制备方法 | |
WO2022100077A1 (zh) | 一种灵敏度高的抗Ro52抗体检测试剂盒 | |
CN111089958A (zh) | 一种基于葡聚糖信号放大的p16INK4a化学发光试剂盒 | |
CN103308681B (zh) | 胰蛋白酶原-2检测试剂盒及制备方法 | |
CN115639367A (zh) | 一种检测抗角蛋白抗体IgG的化学发光免疫试剂盒及应用 | |
CN112255421B (zh) | 一种脂蛋白a检测试剂盒及检测方法 | |
CN105181969A (zh) | 一种中性粒细胞明胶酶相关脂质运载蛋白含量检测试剂盒 | |
CN103175964B (zh) | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 | |
CN109374884A (zh) | 一种pct浓度检测试剂盒及其制备方法 | |
CN113376378A (zh) | 一种d-二聚体检测试剂盒、制备方法及用途 | |
CN111273033A (zh) | 一种高尔基体蛋白73的测定试剂盒及其化学发光测定方法 | |
CN108362892B (zh) | 一种降钙素原胶体金免疫比浊法检测试剂 | |
CN111912990B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN114965986A (zh) | 用于检测血液中可溶性生长刺激表达基因2蛋白(st2)的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Hua Quangao Inventor after: Shen Hexiao Inventor after: Xu Ke Inventor after: Huang Ai Inventor after: Shu Qin Inventor after: Yan Bao Inventor after: Chang Xiangbo Inventor before: Hua Quangao Inventor before: Shen Hexiao Inventor before: Xu Ke Inventor before: Huang Ai Inventor before: Shu Qin Inventor before: Yan Bao Inventor before: Chang Xiangbo |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 2, No. 818, hi tech medical equipment Park, No. 430223, hi tech Road, East Lake Development Zone, Hubei, Wuhan, China. B11 Patentee after: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Address before: 430223 Hubei city of Wuhan province East Lake Development Zone Road, University of Wuhan University of science and Technology Park building four floor Patentee before: Wuhan Life Origin Biotech Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Heart-type fatty acid binding protein content detection kit and preparation method thereof Effective date of registration: 20180612 Granted publication date: 20150415 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: 2018420000024 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190620 Granted publication date: 20150415 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: 2018420000024 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Heart-type fatty acid binding protein content detection kit and preparation method thereof Effective date of registration: 20190813 Granted publication date: 20150415 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: Y2019420000004 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201223 Granted publication date: 20150415 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. Registration number: Y2019420000004 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |